JPRN-UMIN000015531已完成未知
Multicenter Registry for the Optimal Antithrombotic Therapy in the Patients with Arial Fibrillation Undergoing Percutaneous Coronary Intervention Study - MILESTONE Study
Department of Cardiovascular Medicine, Kitasato University School of Medicine0 个研究点目标入组 100 人开始时间: 2014年10月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have already been implanted other DES Patiens with acute myocardial infarction Patients judged by the treating physician to be unsuitable as study subjects
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher DiseaseType 3 Gaucher diseaseMedDRA version: 18.1Level: PTClassification code 10075697Term: Gaucher's disease type ISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003427-38-Outside-EU/EEAShire Human Genetic Therapies6
招募中
1 期
A clinical trial to study the effects of Velaglucerase Alfa Enzyme Replacement Therapy for the treatment of Type 3 Gaucher DiseaseCTRI/2012/05/002666Shire Human Genetic Therapies Inc6
已完成
2 期
An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients with Plasma Therapy-Sensitive Atypical Hemolytic-Uremic Syndrome (AHUS)10018911atypical hemolytic uremic syndromeNL-OMON33473Alexion Pharmaceuticals1
进行中（未招募）
不适用
A randomized, controlled, multicenter clinical trial comparing the efficacy of Peginterferon alfa-2a and ribavirin and metformin versus Peginterferon alfa-2a and ribavirin for the treatment of naïve patients with chronic hepatitis C (CHC) and insulin resistance. - NDCHRONIC ACTIVE HEPATITIS C ASSOCIATED WITH INSULIN RESISTANCEMedDRA version: 6.1Level: PTClassification code 10019744EUCTR2005-003853-29-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
已完成
3 期
A clinical trial to evaluate the efficacy and safety of LC15 - 0444 in patients with type II diabetes.CTRI/2010/091/000353G Life Sciences Ltd180